content_top
43 companies, 1 interpreter! Insight, foresight
and recommendation 

ImmunoCellular Therapeutics, Ltd. (IMUC)

0.27
-0.00
(-0.37%)
Sep 11, 3:59PM EDT
content_middle

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, engages in developing and commercializing immune-based therapies for the treatment of brain, ovarian, and other solid tumors. Its lead pipeline product is ICT-107, a therapeutic dendritic cell (DC) vaccine, which is in Phase IIb clinical trial for the treatment of glioblastoma multiforme (GBM) that is a common and lethal type of brain cancer. The company also develops other therapeutic DC vaccines, such as ICT-121 to treat recurrent GBM, as well as solid tumors, including ovarian, pancreatic, and breast cancers; ICT-140 that targets 7 tumor-associated antigens expressed on ovarian cancer cells; and ICT-109, a monoclonal antibody product candidate to detect pancreatic and lung cancer in plasma and serum. In addition, it has a differential immunization for antigen and antibody discovery (DIAAD) platform that utilizes immunological tolerization to accelerate the discovery of the molecular differences between diseased cells and their normal counterparts. The company is based in Woodland Hills, California.

Previous Close: 
0.27
Open: 
0.27
Bid: 
0.26
Ask: 
0.29
1yr Target Price: 
5.00
Day's Range: 
0.26 - 0.27
52wk Range: 
0.25 - 5.37
Volume: 
749887
Average Daily Volume: 
1665720
Market Capitalization: 
4.26M
Trailing Annual Dividend Yield: 
N/A
Shares Outstanding: 
15841000M
content_right

Pages